Literature DB >> 25606580

De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review.

Gabriel Acosta-Gonzalez1, Jia Qin2, Rosemary Wieczorek3, Jonathan Melamed1, Fang-Ming Deng1, Ming Zhou1, Danil Makarov4, Fei Ye5, Zhiheng Pei1, Matthew R Pincus3, Peng Lee6.   

Abstract

Large cell neuroendocrine carcinoma of the prostate (LCNEC), de novo in particular, is an extremely rare entity that has only been described in the literature in case reports. Historically, the majority of the cases of LCNEC reported in the literature represent typical prostatic adenocarcinomas that transformed after long standing androgen deprivation therapy (ADT). These cases were admixed with histological areas of usual adenocarcinoma and showed hybrid features of both neuroendocrine and usual adenocarcinoma. Here we present a case of an LCNEC without admixed areas of usual prostatic adenocarcinoma arising de novo in a patient without prior history of hormonal therapy. The tumor also shows morphologic evidence of neuroendocrine differentiation; composed of large sheets and nests of cells with moderate amphophilic cytoplasm with peripheral palisading, and vesicular clumpy chromatin with prominent nucleoli. The carcinoma's prostatic origin is indicated by positive immunohistochemical staining for PSA, PAP, PSMA, racemase, and Nkx3.1. Diffusely positive staining for chromogranin and synaptophysin, as well as the presence of secretory granules in the cytoplasm of the tumor cells demonstrated by electron microscopy supports the NE differentiation. NE prostate cancer usually does not express AR and is refractory to ADT therapy while AR and ERG are positive in this case. In summary, we report a de novo LCNEC of the prostate with review of literature, in particular, clinical implications.

Entities:  

Keywords:  Large cell; neuroendocrine; prostate cancer

Year:  2014        PMID: 25606580      PMCID: PMC4297330     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  15 in total

1.  Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.

Authors:  Andrew J Evans; Peter A Humphrey; Jay Belani; Theodorus H van der Kwast; John R Srigley
Journal:  Am J Surg Pathol       Date:  2006-06       Impact factor: 6.394

2.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Scott T Tagawa; Kyung Park; Theresa MacDonald; Matthew I Milowsky; Juan Miguel Mosquera; Mark A Rubin; David M Nanus
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.

Authors:  Arun A Azad; Edward C Jones; Kim N Chi
Journal:  Clin Genitourin Cancer       Date:  2014-03-26       Impact factor: 2.872

Review 4.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 5.  Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations.

Authors:  Samson W Fine
Journal:  Adv Anat Pathol       Date:  2012-07       Impact factor: 3.875

6.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

Authors:  Kyung Park; James T Dalton; Ramesh Narayanan; Christopher E Barbieri; Michael L Hancock; David G Bostwick; Mitchell S Steiner; Mark A Rubin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

7.  Large-cell neuroendocrine carcinoma of prostate. Case report.

Authors:  Luz Maria Moratalla Charcos; Teresa Pastor Navarro; Virginia Cortes Vizcaino; Jose Manuel Osca Garcia; Manuel Gil Salom
Journal:  Arch Esp Urol       Date:  2013-05       Impact factor: 0.436

Review 8.  Aggressive variants of castration-resistant prostate cancer.

Authors:  Himisha Beltran; Scott Tomlins; Ana Aparicio; Vivek Arora; David Rickman; Gustavo Ayala; Jiaoti Huang; Lawrence True; Martin E Gleave; Howard Soule; Christopher Logothetis; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

9.  Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.

Authors:  Jonathan I Epstein; Mahul B Amin; Himisha Beltran; Tamara L Lotan; Juan-Miguel Mosquera; Victor E Reuter; Brian D Robinson; Patricia Troncoso; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

10.  A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Authors:  Xi Wang; Marianna Kruithof-de Julio; Kyriakos D Economides; David Walker; Hailong Yu; M Vivienne Halili; Ya-Ping Hu; Sandy M Price; Cory Abate-Shen; Michael M Shen
Journal:  Nature       Date:  2009-09-09       Impact factor: 49.962

View more
  3 in total

1.  Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor.

Authors:  Charalampos Papagoras; Stella Arelaki; Ioannis Botis; Ioannis Chrysafis; Stavros Giannopoulos; Panagiotis Skendros
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244

2.  A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation.

Authors:  Jimpei Miyakawa; Motofumi Suzuki; Kaori Endo; Yorito Nose; Toshikazu Sato; Yukiko Kishida; Koichi Tamura; Shoujiroh Morinaga; Haruki Kume; Yukio Homma
Journal:  Urol Case Rep       Date:  2018-09-19

3.  Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.

Authors:  Leonidas Apostolidis; Cathleen Nientiedt; Eva Caroline Winkler; Anne Katrin Berger; Clemens Kratochwil; Annette Kaiser; Anne-Sophie Becker; Dirk Jäger; Markus Hohenfellner; Clemens Hüttenbrink; Sascha Pahernik; Florian A Distler; Carsten Grüllich
Journal:  Oncotarget       Date:  2019-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.